Earnings ·
Biofrontera Inc. reported financial results for the second quarter and first half of 2026, ending June 30
BFRIWBiofrontera Inc.
Biofrontera Inc. reported financial results for the second quarter and first half of 2026, ending June 30. Second-quarter net product revenue rose 32.9% to $12.0 million from $9.0 million in the prior-year period, driven by unit volume growth and a price increase. Gross margin improved to 80% from 71%, reflecting a lower cost structure following a strategic transaction with Biofrontera AG. The company reported a net loss of $0.6 million, or $(0.05) per share, compared to a $5.3 million loss in the prior year. Adjusted EBITDA improved significantly to $(0.2) million from $(5.1) million. For the first half of 2026, revenue increased 25.4% to $22.1 million, with a net loss of $5.4 million and adjusted EBITDA of $(3.7) million. Cash used in operating activities for the six-month period was $1.7 million. The company is a biopharmaceutical firm specializing in photodynamic therapy products for dermatological conditions.